Introduction
Kerendia is a prescription medication that contains the active ingredient Finerenone. It is available under the brand name Kerendia. This medication is primarily used for the treatment of certain heart conditions, such as heart failure and reduced heart function after a heart attack.
Uses
Kerendia is prescribed to manage heart failure and reduce the risk of cardiovascular events in patients with reduced heart function after a heart attack. It is used in combination with other medications, such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), to provide comprehensive treatment and improve cardiovascular outcomes.
Dosage and Administration
The dosage of Kerendia may vary depending on individual patient factors and the specific condition being treated. Follow the instructions provided by your healthcare professional or as indicated on the prescription label. Typically, the recommended starting dose is one tablet taken orally once daily. Your healthcare provider may adjust the dosage based on your response to the medication.
Mechanism of Action
The active ingredient in Kerendia, Finerenone, belongs to a class of medications called nonsteroidal mineralocorticoid receptor antagonists. It works by blocking the effects of a hormone called aldosterone, which plays a role in regulating fluid balance and blood pressure. By inhibiting the effects of aldosterone, Kerendia helps reduce fluid retention and improve heart function.
Side Effects
Common side effects may include dizziness, headache, and increased blood potassium levels. Monitor your potassium levels regularly while taking this medication. Serious side effects are rare but may include allergic reactions, severe dizziness, or irregular heartbeat. If you experience any concerning side effects, contact your healthcare provider immediately.
Drug Interactions
Kerendia may interact with other medications, including potassium-sparing diuretics, ACE inhibitors, ARBs, and certain antiarrhythmic medications. These interactions can increase the risk of high blood potassium levels or other adverse effects. Inform your healthcare provider about all the medications you are taking, including prescription, over-the-counter, and herbal products.
Precautions
Before starting Kerendia, inform your healthcare provider about any existing medical conditions, including kidney problems, liver disease, or electrolyte imbalances. This medication is not recommended for use in patients with severe kidney impairment or those who are pregnant or breastfeeding. Avoid excessive consumption of potassium-rich foods or supplements while taking Kerendia.
Storage
Patient Tips
- Take Kerendia exactly as prescribed by your healthcare provider. Do not exceed the recommended dosage or change the dosing schedule without consulting your doctor.
- It may take some time for the full benefits of Kerendia to be realized. Continue taking the medication as directed, even if you feel well.
- If you miss a dose, take it as soon as you remember. However, if it is close to the time for your next dose, skip the missed dose and resume your regular dosing schedule.
- Regular monitoring of your blood pressure, kidney function, and potassium levels may be necessary while taking Kerendia. Follow up with your healthcare provider as recommended.
- Inform your healthcare provider about any new symptoms or changes in your health while taking Kerendia.
- Do not stop taking Kerendia without consulting your healthcare provider, as sudden discontinuation may have adverse effects on your condition.
Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.
References
- Kerendia 10 mg film coated tablets (Health Professionals SmPC) Available at:
- Finerenone (Drugs.com) [Accessed 9 Jun. 2024] (online) Available at:
- finerenone 20 mg tablet (RX) [Accessed 9 Jun. 2024] (online) Available at:
- Finerenone (MedlinePlus) [Accessed 26 Jun. 2024] (online) Available at:
- Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL; FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022 Feb 10;43(6):474-484. doi: 10.1093/eurheartj/ehab777. [Accessed 18 Jun. 2024] Available at:
Reviews
There are no reviews yet.